Almac Clinical Technologies announced today that its Testing Department has completed the ISTQB Software certification.
Almac Testers Receive ISTQB Software Testing Certification
2 July 2008 Yardley, Pennsylvania. Almac Clinical Technologies announced today that its Testing Department has completed the ISTQB Software certification. ISTQB (International Software Testing Qualification Board, Inc.) is the most widely recognized Software Tester certification organization in the world. Almac is one of the first clinical technology organizations to receive this certification. This training assures sponsors that Almac is continuously committed to providing the highest quality technical solutions for its clients.
The testers of Almac Clinical Technologies have been awarded the designation of Certified Tester, Foundation Level (CTFL). The Foundation Level exam tests for software testing knowledge and proficiency, as well the certificate holder's level of familiarity with software testing concepts and industry standard terminology. The Almac Clinical Technologies Testing Department is now part of an elite group of software testers throughout the world that currently hold ISTQB compliant certificates.
Karen Borda, Vice President of Production IT, says “Successfully completing the ISTQB certification for software testing sends another signal to our clients that Almac Clinical Technologies is committed to operational excellence, high-quality service performance, and providing compliant solutions in a timely manner. At Almac we take pride in working consultatively with our clients to understand their needs, gather their trial requirements, and provide innovative solutions for each trial. The ISTQB certification gives us a technological edge over our competitors and reinforces our industry-leading reputation for high quality products supported by our commitment to staff excellence. We aim to be a couple of notches above our competition and this certification supports that goal.”
Jim Murphy, President of Almac Clinical Technologies adds, “At Almac we realize that the power of technology is enhanced through superior project management, customer service and highly-trained employees. Given the technological challenges faced by our clients in the biopharmaceutical industry, Almac Clinical Technologies provides rigorous training for its employees, the ISTQB being just one of many programs we have completed to build our expertise in technology and project management.”
About Almac
Almac Clinical Technologies is a division of the Almac Group that specializes in interactive technology and service solutions to increase the quality and efficiency of the clinical trial process. Our solutions include Interactive Voice and Web Response Systems (IXRS™) for patient randomization; tracking and clinical supply management; iTrial EDC for electronic case report form data collection; electronic patient reported outcome data collection; and web drug reconciliation.
The Almac Group comprises five closely integrated divisions offering a broad range of services from R&D, translational genomic services, API manufacture, formulation development, clinical trial supply and technology (IVRS/EDC), to commercial-scale manufacture. Almac provides services to over 600 companies including all the world leaders in the pharmaceutical and biotech sectors. The company employs over 2,000 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.